Search

Purpose: In this study, the outcomes and flow cytometry results of childhood acute leukemia patients and their relationship with the prognosis and other clinical conditions was investigated. Materials and Methods: A total of 93 patients, including 69 acute lymphoblastic leukemia (ALL) and 24 acute myeloid leukemia (AML) patients diagnosed at our hospital between January 2008 and November 2013, were included. Results: 5-year overall survival (OS) was 66% in ALL patients and 80% in AML patients. When leukemia patients were classified flow cytometrically according to their cell surface antigens (CD); 5-year OS was 77% in CD2(+) patients and 58% in CD2(-) patients. Five-year OS was 82% in patients with CD10(+) and 61% in patients with CD10(-). However, the results were not statistically significant (p>0.05). ALL patients were divided into two groups as ALL with positive T cell markers and ALL with positive B cell markers in the foreground and evaluated accordingly, and the OS of ALL patients with positive T cell markers in the foreground was lower than ALL patients with positive B cell markers in the 5 year (59% and 75%, respectively) (p =0.518). On the other hand, AML patients were divided into two groups as AML with positive lymphoid markers and AML with negative lymphoid markers, and the 5 year OS of AML patients with positive lymphoid markers was higher than AML patients with negative lymphoid markers (83% and 70%, respectively) (p = 0.638). These results were not statistically significant. Conclusion: In the flow cytometric evaluation of our patients with leukemia, it was found that patients with CD10(+) had a better 5-year OS and patients with CD2(+) had a lower 5-year OS. The results of patients with positive B cell markers were better in ALL patients, and the results of patients with positive lymphoid markers were better in AML patients.